Literature DB >> 21749890

Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment.

David C Seldin1, John L Berk, Flora Sam, Vaishali Sanchorawala.   

Abstract

Amyloidotic cardiomyopathy (ACMP) occurs in the setting of rare genetic diseases, blood dyscrasias, chronic infection and inflammation, and advanced age. Cardiologists are on the front lines of diagnosis of ACMP when evaluating patients with unexplained dyspnea, congestive heart failure, or arrhythmias. Noninvasive detection of diastolic cardiac dysfunction and unexplained left ventricular hypertrophy should be followed by biopsy to demonstrate the presence of amyloid deposits and appropriate genetic, biochemical, and immunologic testing to accurately define the type of amyloid. Growing numbers of treatment options exist for these diseases, and timely diagnosis and institution of therapy is essential for preservation of cardiac function.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21749890      PMCID: PMC3135875          DOI: 10.1016/j.hfc.2011.03.009

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  33 in total

Review 1.  Clinical aspects of systemic amyloid diseases.

Authors:  Laura Obici; Vittorio Perfetti; Giovanni Palladini; Remigio Moratti; Giampaolo Merlini
Journal:  Biochim Biophys Acta       Date:  2005-09-02

2.  Tabulation of transthyretin (TTR) variants as of 1/1/2000.

Authors:  L H Connors; A M Richardson; R Théberge; C E Costello
Journal:  Amyloid       Date:  2000-03       Impact factor: 7.141

3.  Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

Authors:  Giovanni Palladini; Carlo Campana; Catherine Klersy; Alessandra Balduini; Giovanbattista Vadacca; Vittorio Perfetti; Stefano Perlini; Laura Obici; Edoardo Ascari; Gianvico Melzi d'Eril; Remigio Moratti; Giampaolo Merlini
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

4.  Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis.

Authors:  John L Berk; Joseph Keane; David C Seldin; Vaishali Sanchorawala; Jun Koyama; Laura M Dember; Rodney H Falk
Journal:  Chest       Date:  2003-09       Impact factor: 9.410

5.  Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

Authors:  Giovanni Palladini; Vittorio Perfetti; Laura Obici; Riccardo Caccialanza; Alessandra Semino; Fausto Adami; Giobatta Cavallero; Roberto Rustichelli; Giovambattista Virga; Giampaolo Merlini
Journal:  Blood       Date:  2003-12-18       Impact factor: 22.113

6.  High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Authors:  Martha Skinner; Vaishali Sanchorawala; David C Seldin; Laura M Dember; Rodney H Falk; John L Berk; Jennifer J Anderson; Carl O'Hara; Kathleen T Finn; Caryn A Libbey; Janice Wiesman; Karen Quillen; Niall Swan; Daniel G Wright
Journal:  Ann Intern Med       Date:  2004-01-20       Impact factor: 25.391

7.  Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins.

Authors:  Angela Dispenzieri; Robert A Kyle; Morie A Gertz; Terry M Therneau; Wayne L Miller; Krishnaswamy Chandrasekaran; Joseph P McConnell; Mary F Burritt; Allan S Jaffe
Journal:  Lancet       Date:  2003-05-24       Impact factor: 79.321

8.  Digoxin sensitivity in amyloid cardiomyopathy.

Authors:  A Rubinow; M Skinner; A S Cohen
Journal:  Circulation       Date:  1981-06       Impact factor: 29.690

9.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Philip R Greipp; Thomas E Witzig; John A Lust; S Vincent Rajkumar; Rafael Fonseca; Steven R Zeldenrust; Christopher G A McGregor; Allan S Jaffe
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

10.  Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress.

Authors:  Daniel A Brenner; Mohit Jain; David R Pimentel; Bo Wang; Lawreen H Connors; Martha Skinner; Carl S Apstein; Ronglih Liao
Journal:  Circ Res       Date:  2004-03-25       Impact factor: 17.367

View more
  3 in total

1.  Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.

Authors:  Vaishali Sanchorawala
Journal:  Am J Blood Res       Date:  2012-01-01

2.  Sudden cardiac arrest secondary to cardiac amyloidosis in a young woman with cryopyrin-associated periodic syndrome.

Authors:  Keiko Endo; Atsushi Suzuki; Kayoko Sato; Tsuyoshi Shiga
Journal:  BMJ Case Rep       Date:  2015-04-16

3.  Cardiac Amyloidosis, An Infiltrative Heart Disease Presenting as Arrhythmia-A Case Report.

Authors:  B Magesh; Deepak Kadeli; Sunil Bohra; V Krishnaprasath; R Keshava
Journal:  J Clin Diagn Res       Date:  2017-04-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.